Business · 10/05/2024Updated: 10/16/2026 · 1 min read
Prospective Grant of an Exclusive Patent License: Antibody-Drug Conjugates (ADCs) for Targeting CD56-Positive Tumors
Summary
The National Cancer Institute is contemplating the grant of an Exclusive Patent License to McSAF Inside Oncology SAS for practicing inventions related to CD56-Positive Tumors.